Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 2008

View Archived Issues

Actelion offers Q3 pipeline progress report

GSK-923295 development continues in vivo and in phase I

Positive results for novel Plk-1 inhibitor BI-6727 in advanced solid tumors

Exelixis discloses new investigational compounds for cancer

Sanofi-aventis: Q3 overview

Pharmacological profile of phase III PAH drug macitentan published

Plethora reports positive results from phase III efficacy study of PSD-502 for PE

Research and Markets adds GTC Biotherapeutics' company profile to their offering

Eisai reviews H1 pipeline progression

Evolva receives funding from the Global Cardiovascular Innovation Center

InNexus develops new EGFR antibody targeting colorectal cancer

Antibacterial properties of a novel aryloxy-phenol Fab-I inhibitor, MUT-37307, presented

Novel JAK-1/JAK-2 inhibitor shows beneficial effects in experimental arthritis studies

New agents for gout disclosed in recent Kotobuki patent

Daiichi Sankyo and Sanofi Pasteur launch ActHIB vaccine in Japan

FDA establishes target action date of April 17, 2009 for Surfaxin

Raptor collaborates with Centre Hospitalier Universitaire d'Angers on Huntington's disease trial

Nanogen and Menarini sign agreement to commercialize IVD infectious disease kits

iCo Therapeutics reports positive results from animal studies of iCo-009 in visceral leishmaniasis

Novel analgesic agents imparted in recent GSK patent

Recent patents disclose new antiinfective agents

Novel glutaminyl cyclase inhibitors patented by Probiodrug

Studies describe activity of novel antifungal FG-3409

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...